Novocol Pharmaceutical of Canada, Inc.June 18, 2019

FDA 483 - Novocol Pharmaceutical of Canada, Inc. - June 18, 2019

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Novocol Pharmaceutical of Canada, Inc.

Record Details

Novocol Pharmaceutical of Canada, Inc. was cited for three observations during an FDA inspection. The firm failed to follow established procedures for preventing microbiological contamination of sterile drug products, including visual inspection qualification and semi-automated inspection protocols. Additionally, the company did not properly document and evaluate recurring priority 1 alarms as required by its alarm response procedure.

Company: Novocol Pharmaceutical of Canada, Inc.
Inspection Date: June 18, 2019
Product Type: Drugs
Office: Office of Biological Products Operations - Division I
Person: Bei Y. He

Open in Dashboard

ID · 7485559c-7f8a-451d-a20e-1683858db483